57 related articles for article (PubMed ID: 2461688)
1. Carcinoid Syndrome: A Review.
Gade AK; Olariu E; Douthit NT
Cureus; 2020 Mar; 12(3):e7186. PubMed ID: 32257725
[TBL] [Abstract][Full Text] [Related]
2. What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators.
Mulders MCF; de Herder WW; Hofland J
Endocr Rev; 2024 May; 45(3):351-360. PubMed ID: 38038364
[TBL] [Abstract][Full Text] [Related]
3. Charles Darwin's Mitochondrial Disorder: Possible Neuroendocrine Involvement.
Hayman J; Finsterer J
Cureus; 2021 Dec; 13(12):e20689. PubMed ID: 34966625
[TBL] [Abstract][Full Text] [Related]
4. Flushing in (neuro)endocrinology.
Hannah-Shmouni F; Stratakis CA; Koch CA
Rev Endocr Metab Disord; 2016 Sep; 17(3):373-380. PubMed ID: 27873108
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic Flushing with Dysesthesia: Treatment with the 585nm Pulsed Dye Laser.
Fogelman JP; Stevenson ML; Ashinoff R; Soter NA
J Clin Aesthet Dermatol; 2015 Aug; 8(8):36-41. PubMed ID: 26345489
[TBL] [Abstract][Full Text] [Related]
6. Tubulovillous adenoma of the duodenum: a new etiology for flushing and urinary 5-HIAA elevation.
Betchen SA; Cirigliano M; Furth EE; Broussard D; Grippi M; Lichtenstein GR
Dig Dis Sci; 1998 Jul; 43(7):1474-81. PubMed ID: 9690381
[No Abstract] [Full Text] [Related]
7. Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastasis.
Jackson JA; Shipman HD
West J Med; 1989 Oct; 151(4):461-3. PubMed ID: 2588586
[No Abstract] [Full Text] [Related]
8. Pathophysiological causes and clinical significance of flushing.
Ray D; Williams G
Br J Hosp Med; 1993 Nov 17-Dec 14; 50(10):594-8. PubMed ID: 8293240
[TBL] [Abstract][Full Text] [Related]
9. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing features of idiopathic flushing and carcinoid syndrome.
Aldrich LB; Moattari AR; Vinik AI
Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
[TBL] [Abstract][Full Text] [Related]
11. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
12. [Pronounced flush symptoms in carcinoid syndrome without liver metastases].
Roth J; Raschka C; Hammar CH
Leber Magen Darm; 1994 Nov; 24(6):259-61. PubMed ID: 7531269
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
